Medical expert of the article
New publications
Preparations
Ongliza
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Onglise is a drug with antidiabetic activity. The drug contains the active ingredient - substance Saksagliptin, which is an extremely powerful selective element with a reversible inhibiting effect of a competitive type, exerted in relation to the element dipeptidyl peptidase-4.
The drug is prescribed for use in monotherapy or in combination with other medicinal substances prescribed for the treatment of diabetes mellitus, having an insulin-independent nature.
Indications Ongliza
It is used in the case of diabetes mellitus of the 2nd subtype - in the form of an addition to diet and physical procedures, in order to improve glycemic control. Usually used in such schemes:
- monotherapy;
- initial combination therapy with metformin;
- combination with monotherapy, which uses metformin, thiazolidinediones and sulfonylurea derivatives - in the absence of proper glycemic control during such treatment.
Pharmacodynamics
When diabetics use medications, the activity of the enzyme DPP-4 inside their body is inhibited for a 24-hour period.
After oral administration of glucose, as a result of a slowdown in the activity of DPP-4, a 2-3-fold increase in the values of the glucose-dependent polypeptide insulinotropic character, as well as glucagon-like peptide-1, is carried out. In addition, there is a decrease in indicators of glucagon and potentiation of the glucose-dependent response of β-cells. Due to this, the level of C-peptide increases inside the body along with insulin.
The release of insulin through the pancreatic β-cells, as well as the weakening of glucagon release from pancreatic α-cells, causes a decrease in fasting glycemia, as well as a decrease in postprandial glycemia.
Taking saxagliptin does not cause weight gain in patients.
[3]
Pharmacokinetics
Inside the body, saxagliptin is absorbed at high speed when consumed before meals. With the introduction of the inside absorbed about 75% of the dosage. With blood protein, saxagliptin with its metabolic element is rather poorly synthesized.
Indicators of plasma Cmax saxagliptin along with its main metabolic component are recorded after 2 and 4 hours, respectively.
The average duration of the final half-life of the substance and metabolite is 2.5 and 3.1 hours, respectively. Excretion is carried out with urine and bile.
[4]
Dosing and administration
The drug is taken orally, without reference to food intake.
When carrying out monotherapy, Ongliz is used in a dosage of 5 mg of the substance 1 time per day.
In the case of complex therapy, 5 mg of the drug should be taken together (1 time per day) to use metformin, sulfonylurea derivatives or thiazolidinedione.
At the initial stage of therapy in combination with metformin, the dose of drugs is 5 mg, and the dosage of metformin is 0.5 g per day.
If you miss the use of medication is required to take it immediately, as the drug will be remembered. Double serving is prohibited.
Persons with poor renal function in severe or moderate stages, and in addition, people who are on hemodialysis procedures, should use 2.5 mg of the substance per day. Reception should be carried out after a hemodialysis session.
When used together with powerful substances that slow down the activity of the component CYP 3A4 / 5, the serving size of Onglyza should be 2.5 mg per day.
[6]
Use Ongliza during pregnancy
Due to the lack of data regarding the use of saxagliptin during breastfeeding, as well as pregnancy, during these periods the medicine is not used.
Contraindications
The main contraindications:
- diabetes mellitus of the 1st subtype;
- use of the medication along with insulin;
- lactose intolerance, galactosemia, congenital glucose-galactose malabsorption;
- ketoacidosis having a diabetic nature;
- hypersensitivity associated with the elements of the drug.
Extreme caution should be used in patients with kidney failure (severe or moderate), the elderly and patients who use sulfonylurea derivatives.
[5]
Side effects Ongliza
Among the possible adverse events:
- infections affecting the upper region of the respiratory tract or urethra;
- sinusitis;
- vomiting or gastroenteritis;
- headaches.
When combining medication with metformin, headaches or nasopharyngitis may occur.
Interactions with other drugs
Information obtained as a result of testing, showed that a significant interaction of the drug with other drugs develops only individually.
Combination with substances that induce CYP 3A4 / 5 isoenzymes (rifampicin with carbamazepine, dexamethasone and phenytoin with phenobarbital among them) can reduce the performance of the main metabolic element of saxagliptin.
Because sulfonylurea derivatives can lead to the development of hypoglycemia, to reduce this risk, when combined with Ongliza, it may be necessary to lower the dosage of agents that are sulfonylurea derivatives.
Attention!
To simplify the perception of information, this instruction for use of the drug "Ongliza" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.